<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60405">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01913535</url>
  </required_header>
  <id_info>
    <org_study_id>RAP-003</org_study_id>
    <nct_id>NCT01913535</nct_id>
  </id_info>
  <brief_title>Proof-of-Concept Trial of LY2456302 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression</brief_title>
  <official_title>Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of LY2456302, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brown University-Butler Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of
      oral LY2456302 for treating patients with treatment resistant depression who are taking an
      antidepressant that is not working for them.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression - 6 items</measure>
    <time_frame>Past 48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This instrument is completed with a structured interview guide by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week. The time frame for this scale is the past 48 hours.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">91</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Low Dose Drug-Drug Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive LY2456302 10.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Drug-Drug Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive LY2456302 20.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Low-Dose Drug Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm will receive placebo for 3 days (in Phase 1) and LY2456302 10.0 mg/day for 3 days (in Phase 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/High-Dose Drug Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm will receive placebo for 3 days (in Phase 1) and LY2456302 20.0 mg/day for 3 days (in Phase 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm will receive placebo for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2456302</intervention_name>
    <description>Dose of LY2456302 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days)</description>
    <arm_group_label>Low Dose Drug-Drug Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2456302</intervention_name>
    <description>Dose of LY2456302 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days)</description>
    <arm_group_label>High Dose Drug-Drug Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2456302</intervention_name>
    <description>For patients randomly assigned to the placebo/low-dose drug sequence, the dose of LY2456302 will be 10 mg/day during the second phase of the study (3 days)</description>
    <arm_group_label>Placebo/Low-Dose Drug Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2456302</intervention_name>
    <description>For patients randomly assigned to the placebo/high-dose drug sequence, the dose of LY2456302 will be 20 mg/day during the second phase of the study (3 days)</description>
    <arm_group_label>Placebo/High-Dose Drug Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days)</description>
    <arm_group_label>Placebo/Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18-65 years old.

          -  Able to read, understand, and provide written, dated informed consent prior to
             screening.

          -  Diagnosed with Major Depressive Disorder (MDD), single or recurrent, and currently
             experiencing a Major Depressive Episode (MDE) of at least eight weeks in duration,
             prior to screening.

          -  Has a history of TRD during the current MDE.

          -  Meet the threshold on the total MADRS score of greater than or equal to 20 at both
             screening and baseline visits (Day -5/-14 and Day 0), as confirmed by the remote
             centralized MGH CTNI rater between the screen visit and the baseline visit.

          -  In good general health

          -  For female participants, status of non-childbearing potential or use of an acceptable
             form of birth control

          -  Body mass index between 18-35 kg/m2

          -  Concurrent psychotherapy will be allowed if the type and frequency of the therapy has
             been stable for at least three months prior to screening and is expected to remain
             stable during participation in the study

          -  Concurrent benzodiazepine and hypnotic therapy will be allowed if the therapy has
             been stable for at least 4 weeks prior to screening and if it is expected to remain
             stable during the course of the subject's participation in the study.

        Exclusion Criteria:

          -  Female of childbearing potential who is not willing to use one of the specified forms
             of birth control during the study

          -  Female that is pregnant or breastfeeding

          -  Female with a positive pregnancy test at screening or baseline

          -  History during the current MDE of failure to achieve a satisfactory response to &gt;3
             treatment courses of a therapeutic dose of an antidepressant therapy of at least 8
             weeks duration during the current episode

          -  Total MADRS score of &lt;20 at the screen or baseline visits, or as assessed by the
             remote, independent MGH CTNI rater and reported to the site

          -  Current diagnosis of a Substance Use Disorder (Abuse or Dependence) with the
             exception of nicotine dependence, at screening or within six months prior to
             screening

          -  Current diagnosis of Axis I disorders other than Dysthymic Disorder, Generalized
             Anxiety Disorder, Social Anxiety Disorder, Panic Disorder or Specific Phobia (unless
             one of these is comorbid and clinically unstable, and/or the focus of the
             participant's treatment for the past 6 months or more)

          -  History of bipolar disorder, schizophrenia or schizoaffective disorders, or any
             history of psychotic symptoms in the current or previous depressive episodes

          -  History of eating disorders within five years of screening

          -  Any Axis I or Axis II Disorder, which at screening is clinically predominant to their
             MDD or has been predominant at any time within 6 months prior to screening

          -  Subject is considered at significant risk for suicidal behavior during the course of
             their participation in the study

          -  Subject has had electroconvulsive therapy in the current episode of depression

          -  Has received vagus nerve stimulation (VNS) at any time prior to screening

          -  Dementia, delirium, amnestic, or any other cognitive disorder

          -  Has a clinically significant abnormality on the screening physical examination

          -  Participation in any clinical trial with an investigational drug or device within the
             past month or concurrent to study participation

          -  Known history or current episode of: Uncontrolled hypertension, Recent myocardial
             infarction (within one year) or a history of more than one myocardial infarction,
             Syncopal event within the past year, Congestive heart failure, Angina pectoris,
             Systolic BP &lt;85 or &gt;160 mmHg or diastolic BP &gt;95 mmHg or heart rate &lt;50 or &gt;105 beats
             per minute at screening or randomization, or QTcF greater than or equal to 450 msec
             at screening or randomization.

          -  Chronic lung disease

          -  Lifetime history of surgical procedures involving the brain or meninges,
             encephalitis, meningitis, degenerative central nervous system disorder, epilepsy,
             mental retardation, or any other disease/procedure/accident/intervention associated
             with significant injury to or malfunction of the central nervous system, or a history
             of significant head trauma within the past 2 years

          -  Presents with a history of Thyroid stimulating hormone outside of the normal limits
             and clinically significant as determined by the investigator

          -  Patients with diabetes mellitus fulfilling any of the following criteria:

               1. Unstable diabetes mellitus defined as glycosylated hemoglobin (HbA1c) &gt;8.5% at
                  screening

               2. Admitted to hospital for treatment of diabetes mellitus or diabetes mellitus
                  related illness in the past 12 weeks

               3. Not under physician care for diabetes mellitus

               4. Has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the
                  4 weeks prior to screening. For thiazolidinediones (glitazones) this period
                  should not be less than 8 weeks.

               5. Any other clinically significant abnormal laboratory result (as determined after
                  evaluation by study investigator and MGH CTNI medical monitor) at the time of
                  the screening exam.

          -  History of hypothyroidism and has been on a stable dosage of thyroid replacement
             medication, or was surgically treated less than six months prior to screening

          -  History of hyperthyroidism which was treated (medically or surgically) less than six
             months prior to screening

          -  Any current or past history of any physical condition which in the investigator's
             opinion might put the subject at risk or interfere with the interpretation of study
             results

          -  History of positive screening urine test for drugs of abuse

          -  Patients with exclusionary laboratory values, or requiring treatment with
             exclusionary concomitant medications, including tricyclic antidepressants and
             monoamine oxidase inhibitors, or on two or more concomitant antidepressant therapies

          -  Patients currently taking a proton pump inhibitor (PPI)/histamine 2 (H2) blocker or
             with a history of chronic NSAID use

          -  Patients with a positive test for Helicobacter pylori (urea breath test)

          -  Patients with any of the following GI-related findings:

               1. Clinically evident GI complaints or GI disease at Screening or Visit 1

               2. Past history of gastric disease (including but not limited to peptic ulcer
                  disease, gastritis (including atrophic gastritis), upper GI bleeding, any other
                  GI precancerous conditions), and of any other clinically relevant GI disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Fava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital (Coordinating Center)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda L Carpenter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University-Butler Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Zajecka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary F Morrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheldon H Preskorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Kimball, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maurizio Fava, MD</last_name>
    <phone>617-724-0838</phone>
    <email>mfava@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martina Flynn</last_name>
    <phone>617-643-6028</phone>
    <email>mflynn2@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Zajecka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sheldon H Preskorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>James Kimball, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mary F Morrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University-Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Linda L Carpenter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 30, 2013</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Maurizio Fava, MD</investigator_full_name>
    <investigator_title>Overall Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Treatment Resistant Depression</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
